InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing ...

CEO Mitchell Steiner stated that Veru is advancing its late-stage clinical pipeline, focusing on two oral small molecule drugs: enobosarm, a selective androgen receptor modulator for combination with ...

Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity on track to initiate this ...

Our circadian clocks play a crucial role in our health and well-being, keeping our 24-hour biological cycles in sync with light and dark exposure. Disruptions in the rhythms of these clocks, as with ...

The first study on deuterium-depleted water (DDW) concluded that a higher D/H ratio inside cells can trigger cell division.

When UNSW Associate Professor Shafagh Waters explains cystic fibrosis (CF) to the children she works with, she asks them to ...

Year-end report discusses combination therapy’s Mechanism of Action activating both innate and adaptive immune responses ...

OVATION 3 is IMUNON’s pivotal Phase 3 study of IMMN-001, an IL-12 gene-mediated immunotherapy, in women with advanced stage epithelial ovarian cancer. The study is supported with unprecedented overall ...

The FDA approved a fixed-dose combination of carbachol and brimonidine tartrate for presbyopia, offering a noninvasive ...

OMEICOS, a clinical-stage biopharmaceutical company developing first-in-class small molecule therapeutics for mitochondrial and inflammatory disorders, announced the successful conclusion of its multi ...

Gene Expression Data Show Direct Impact on the Core Biology of IPF ...